Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Kiniksa Pharmaceuticals International, PLC

KNSA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$80.20

▲ +1.03%

Market Cap $6.26B · Vol 96.34K

Key Metrics

P/E Ratio

81.59

FWD: 50.64

Market Cap

$6.26B

Mid Cap

Div Yield

N/A

EPS Growth

+52.80%

YoY

RSI (14)

57.78

Momentum

Beta

0.09

vs Market

52W High

$82.68

3.00% below

52W Low

$32.89

143.84% above

Volume

96.34K

Avg 186.73K

P/B

5.54

Price-to-book

ROE

11.73%

Return on equity

Free Float

95.59%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Kiniksa Pharmaceuticals International, PLC (KNSA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does KNSA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.89%

+27.63%

+50.64%

+87.56%

YTD

+94.42%

+142.74%

+359.60%

+522.19%

Financials & Valuation

TTM · Annual

Total Revenue	$677.56M
Net Income	$59.01M
Revenue Growth (YoY)	+55.36%
Gross Margin	88.54%
Operating Margin	11.40%
Net Profit Margin	8.71%
ROE	11.73%
ROA · ROIC	13.22% · 11.73%

P/E Ratio	81.59
Forward P/E (FY1)	50.64
PEG Ratio	0.25
P/S	4.81
P/B	5.54
P/FCF	23.88
EPS Growth	+52.80%
Outstanding Shares	78.02M

Technical Indicators

50-Day SMA	$68.15
200-Day SMA	$51.32
RSI (14)	57.78
Beta	0.09
52-Week High	$82.68
52-Week Low	$32.89

Volume Today	96.34K
Avg Daily Volume (30D)	186.73K
Relative Volume	0.52x
Volatility (10D)	24.63
Volatility (30D)	71.03
Free Float	95.59%

Analyst Consensus

BUY

Current Price $80.20

Mean Target $96.71

52W Low$32.89 52W High$82.68

Current

Target

$32.89 $82.68

Current Analyst target

+20.59% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00KT2KGM7

ISINGB00BRXB0C07

CountryUnited Kingdom

Sub-IndustryBiopharmaceuticals

Earnings DateOct 26, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc +0.61% CSL.AX CSL Ltd +2.68% 207940.KS Samsung Biologics Co Ltd +0.76% UCB.BR Ucb SA +1.86% BIIB Biogen Inc +1.21%

Company Profile

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.